Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

Aman U. Buzdar; Charles K. Tashima; George R. Blumenschein; Gabriel N. Hortobagyi; Hwee‐Yong ‐Y Yap; Allan N. Krutchik; Gerald P. Bodey; Robert B. Livingston

doi:10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7

Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

Aman U. Buzdar
, Charles K. Tashima
, George R. Blumenschein
, Gabriel N. Hortobagyi
, Hwee‐Yong ‐Y Yap
, Allan N. Krutchik
, Gerald P. Bodey
, Robert B. Livingston

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m² I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.

Original language	English (US)
Pages (from-to)	392-395
Number of pages	4
Journal	Cancer
Volume	41
Issue number	2
DOIs	https://doi.org/10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7
State	Published - Feb 1978
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7

Cite this

@article{9c02361d201f4582bafa7e083e7f404b,

title = "Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy",

abstract = "Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4\% achieved complete remission (CR), 23\% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.",

author = "Buzdar, \{Aman U.\} and Tashima, \{Charles K.\} and Blumenschein, \{George R.\} and Hortobagyi, \{Gabriel N.\} and Yap, \{Hwee‐Yong ‐Y\} and Krutchik, \{Allan N.\} and Bodey, \{Gerald P.\} and Livingston, \{Robert B.\}",

year = "1978",

month = feb,

doi = "10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7",

language = "English (US)",

volume = "41",

pages = "392--395",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

AU - Buzdar, Aman U.

AU - Tashima, Charles K.

AU - Blumenschein, George R.

AU - Hortobagyi, Gabriel N.

AU - Yap, Hwee‐Yong ‐Y

AU - Krutchik, Allan N.

AU - Bodey, Gerald P.

AU - Livingston, Robert B.

PY - 1978/2

Y1 - 1978/2

N2 - Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.

AB - Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.

UR - https://www.scopus.com/pages/publications/0017801135

UR - https://www.scopus.com/pages/publications/0017801135#tab=citedBy

U2 - 10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7

DO - 10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7

M3 - Article

C2 - 630529

AN - SCOPUS:0017801135

SN - 0008-543X

VL - 41

SP - 392

EP - 395

JO - Cancer

JF - Cancer

IS - 2

ER -

Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this